CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.
CDR-Life AG has raised $76.0M in total funding. The most recent round was Series A. The last funding was announced in April 2022.
CDR-Life AG's investors include RA Capital Management, Jeito Capital, Omega Funds.
CDR-Life AG is headquartered in Schlieren, Switzerland.
CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.
CDR-Life AG is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CDR-Life AG — Funding & Investors." VCBacked, April 13, 2022, https://www.vcbacked.co/company/cdr-life-ag. Accessed August 14, 2026.
VCBacked. (2022). CDR-Life AG — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/cdr-life-ag
{{cite web |title=CDR-Life AG — Funding & Investors |url=https://www.vcbacked.co/company/cdr-life-ag |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated